JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Investing.com - RBC Capital raised its price target on American Healthcare REIT, Inc (NYSE:AHR) to $45.00 from $39.00 on Wednesday, while maintaining an Outperform rating on the stock. The company’s shares, currently trading at $40.27, have delivered an impressive 137% return over the past year, with analysts maintaining a strong buy consensus.
The price target increase follows American Healthcare REIT’s second-quarter 2025 earnings report, which RBC Capital described as showing "solid results" for the healthcare real estate investment trust.
RBC Capital highlighted a stronger organic growth outlook for the company, primarily driven by its Trilogy segment, as a key factor behind the revised target.
The firm also noted a "better investment pace" demonstrated by American Healthcare REIT in its latest quarterly performance.
RBC Capital ranks American Healthcare REIT’s growth outlook "among best in healthcare sector," according to its analysis of the company’s recent financial performance.
In other recent news, American Healthcare REIT reported its financial results for the second quarter of 2025, highlighting a strong performance. The company posted Core Funds From Operations (FFO) of $0.42 per share, surpassing both JMP Securities’ expectation of $0.39 and the consensus estimate of $0.40 per share. This earnings beat was largely due to higher net operating income from the company’s RIDEA assets. Additionally, American Healthcare REIT saw a significant 27% increase in normalized funds from operations per share. The company also raised its full-year 2025 NFFO guidance, reflecting a positive outlook. Following these developments, JMP Securities raised its price target for the company to $45.00 from $40.00 while maintaining a Market Outperform rating. These recent updates indicate a period of growth and positive investor sentiment for American Healthcare REIT.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.